1．报告期内,公司不存在控股股东及其他关联方占用公司资金的情况，也不 存在其他以前年度发生但延续到本年末的控股股东及其关联方非正常占用公司 资金的情况。 2．公司不存在为股东、股东的控股子公司、股东的附属企业及本公司其他 关联方、任何非法人单位或个人提供担保的情况。 3．报告期内，公司发生的担保事项均为公司、子公司间相互提供担保，并 且均履行了必要的审批程序和信息披露义务，符合相关法律法规的规定。报告期 内未发生违规对外担保事项，也不存在逾期担保、涉及诉讼的担保及因担保被判 决败诉而应承担损失等情况。 二、关于公司《2023 年限制性股票激励计划（草案）》及其摘要的独立意 见 光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 独立董事关于第五届董事会第十九次会议相关事项的独立意见 根据《公司法》、《证券法》、《关于在上市公司建立独立董事的指导意见》、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、 《公司章程》及《独立董事工作制度》的有关规定，我们作为光正眼科医院集团 股份有限公司（以下简称"公司"）的独立董事，出席了公司 2022 年 8 月 23 日召开的第五届董事会 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-066 光正眼科医院集团股份有限公司 第五届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）第五届董事会第十九 次会议于 2023 年 8 月 23 日（星期三）以现场结合通讯方式召开。本次会议应到 会董事 9 人，实际出席董事 9 人，公司部分高级管理人员列席了会议，会议由董 事长周永麟先生主持，会议的召集、召开程序及参加表决的董事人数符合《公司 法》、《公司章程》等有关法律、法规的规定，合法、有效。经与会董事认真审 议本次会议议案并表决，形成本次董事会决议如下： 表决结果：同意 6 票；反对 0 票；弃权 0 票；回避 3 票。 1 光正眼科医院集团股份有限公司 公司独立董事对本议案发表了同意的独立意见。 一、审议通过《2023 年半年度报告全文及摘要》 董事会认为：公司 2023 年半年度报告全文及摘要的编制和审核程序符合法 律、行政法规、中国证监会的规定，报告内容真实、准确、完整地反映 ...

光正眼科医院集团股份有限公司 2.控股股东股份累计质押的情况 证券代码：002524 证券简称：光正眼科 公告编号：2023-064 光正眼科医院集团股份有限公司 关于控股股东部分股份质押续期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次股份质押的基本情况 光正眼科医院集团股份有限公司（以下简称"公司"）近日接到控股股东光 正投资有限公司（以下简称"光正投资"）函告，获悉光正投资将所持有本公司 的部分股份办理了质押续期的相关手续，具体情况如下： 1.本次股份质押续期的基本情况 注：本次质押续期不涉及负担重大资产重组等业绩补偿义务。 | 股东名称 | 是否为 控股股 东或第 一大股 | 本次 质押续期 | 占其所持 股份 | 占公司 总股本 | 是否 为限 | 是否 为补 充质 | 质押 | 续期后 | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其 一致行 | 数量 （股） | 比例 | 比例 | 售股 | 押 ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-063 光正眼科医院集团股份有限公司 关于回购股份方案实施完成暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 7 月 18 日召开了第五届董事会第十八次会议和第五届监事会第十四次会议，逐项审议通 过了《关于回购公司股份方案的议案》，同意公司以集中竞价方式回购公司部分 社会公众股份，回购价格不超过人民币 9.00 元/股（含），回购股份数量为 100 万股（含）-150 万股（含），根据本次回购数量及回购价格上限测算，回购资 金总额区间为 900 万元（含）-1350 万元（含），具体回购金额以回购期满时实 际回购股份使用的资金为准，资金来源均为自有资金。实施期限为自董事会审议 通过回购股份方案之日起 12 个月内。公司于 2023 年 7 月 21 日披露了《关于回 购公司股份事项前十名股东持股信息的公告》和《关于回购公司股份的回购报告 书》，具体内容详见公司发布在指定媒体的公告（公告编 ...

Group 1: Company Overview and Market Position - Guangzheng Eye Hospital Group is a nationwide eye care service provider with 14 clinics across major cities, including Shanghai, Wuxi, and Chengdu, capturing significant market share in local areas [2][4]. - The company reported a cataract revenue share of 60-70% and an increase in refractive income from approximately 7% to 16% from 2018 to 2022 [2][3]. - The company aims to maintain a growth rate of 20-30% over the next few years, aligning with the overall industry growth [6][8]. Group 2: Financial Performance and Projections - The net profit attributable to the parent company is projected to be 36 million RMB for the year, with a target of 4-6 million RMB for the first half [6][8]. - The company achieved a gross margin of 49% for cataract surgeries as of Q1 2023, indicating a competitive advantage [3][8]. - The revenue from refractive services is expected to reach nearly 1 billion RMB this year, reflecting significant growth in this segment [5][6]. Group 3: Strategic Initiatives and Acquisitions - Following the acquisition of New Vision in 2018, the company has focused on enhancing its service offerings and expanding into consumer healthcare [3][4]. - The company has established strategic partnerships with academic institutions and suppliers to bolster its research and development capabilities [3][6]. - The company plans to integrate its external assets, including Meier Eye Hospital and Suzhou Eye, into the listed company structure as they mature [5][6]. Group 4: Operational Efficiency and Cost Management - The company has implemented measures to reduce sales expenses, including enhancing brand reputation and customer service [7][8]. - The operational structure separates new and old business units, ensuring independent management and financial accountability [6][7]. - The company aims to improve operational efficiency by replicating successful models from Shanghai and Wuxi in other regions [6][8].

Group 1: Financial Performance - The company's budget for 2023 is projected at a revenue of 1.1 billion and a net profit of 36 million [5] - The net profit margin for the ophthalmology segment is expected to recover to 6%-8% for the full year of 2023 [3] - The company aims for a 48% increase in revenue compared to 2022 [5] Group 2: Market Strategy - The company focuses on regional scale development, targeting five major city clusters: Yangtze River Delta, Pearl River Delta, Beijing-Tianjin-Hebei, Jiaodong Peninsula, and Chengdu-Chongqing [2][3] - These five core city clusters account for one-third of China's population and 50% of its GDP, indicating a concentrated demand for ophthalmic medical services [2] - The company has established 14 specialized ophthalmology hospitals and 2 optometry clinics across major cities, maintaining a leading position in the private ophthalmology sector [6] Group 3: Business Expansion - The company is pursuing both organic growth and external expansion, with plans to acquire and inject profitable targets into the company [6][9] - Current successful hospitals generate annual revenues ranging from 150 million to 300 million [9] - The company has initiated external layouts, such as partnerships with Meiermu and Suzhou Ear, Nose, and Throat Hospital [2][9] Group 4: Service and Product Development - The company is enhancing its service offerings, with a focus on cataract surgery, which has seen a rise in high-end lens surgery from 50% in 2021 to 77% in Q1 2023 [3] - The proportion of refractive income has increased from approximately 25% in 2018 to 44% in 2022, while optometry income rose from 7% to 16% in the same period [3] - The company plans to develop a comprehensive approach to eye care, focusing on cataracts, refractive surgery, and optometry [3] Group 5: Operational Efficiency - The company is implementing measures to reduce sales and management expense ratios, which have already seen a decline in 2022 [5] - A focus on improving operational efficiency and resource allocation is underway, with the establishment of six business units to enhance management quality [5][6] - The company is exploring the integration of AI technologies, such as ChatGPT, to improve patient services and operational efficiency [3]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2023-045 光正眼科医院集团股份有限公司 关于参加 2023 年新疆辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，光正眼科医院集团股份有限公司（以下 简称"公司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年新疆辖区上市公司投资者网上集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP， 参与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）15:30-18:00。届时 公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ 特此公告。 光正眼科医院集团股份有限公司董事会 二〇二三年六月十三日 ...

光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 编号：2023-002 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 □√业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称 通过网络方式参加公司 2022 年度业绩网上说明会的投资者 时间 2023 年 5 月 12 日（星期五）下午 15：00-17：00 地点 全景网 http://www.p5w.net/ 上市公司接待 人员姓名 公司董事长、总经理周永麟先生；独立董事郑石桥先生；董事、 副总经理王建民先生；董事、财务总监李俊英女士；董事会秘 书李薇女士； 投资者关系活 动主要内容介 绍 1.今年的还有业绩对赌协议吗？ 答：公司收购新视界眼科的业绩对赌期已结束，今年无业 绩对赌协议。 2.请问公司关于对新视界重大资产重组业绩补偿诉讼的进 展如何？ 答：您好！关于新视界重大资产重组业绩补偿诉讼案已于 2022 年 8 月 31 日一审判决，且判决结果已生效。详情请见公司 发布在指定媒体的公告（公告编号：2022-067、2022-069）。 根据本次判决结果，公司减少支付股权转让款合计 21,200 万 ...

Financial Performance - In 2022, the company's overall revenue declined due to limited operational time in Shanghai, with over 50% of revenue concentrated in that region [3] - In Q1 2023, revenue increased by 16.23% year-on-year, with the ophthalmology segment growing by 31% [3] - The net profit margin for the ophthalmology segment reached 10.5% in March 2023, with an annual forecast of around 6.7% [4] Strategic Development - The company aims to focus on ophthalmology as its core business, having divested over 1 billion in non-core assets [3] - The strategic focus includes regional expansion in key urban areas, targeting cities that account for one-third of the population and 50% of GDP in China [4] - The company plans to enhance its ophthalmology service structure, with cataract services stabilizing at a growth rate of around 10%, while refractive and optometry services maintain a high growth rate of 20-30% [4] Operational Improvements - The company has implemented over a hundred training sessions for medical staff and optimized clinical guidelines to improve service quality [3] - The proportion of high-end cataract surgeries has increased from 50% in 2021 to 77% in Q1 2023 [4] - The company has established partnerships with universities for talent recruitment and has implemented an equity incentive plan to retain key personnel [6] Market Positioning - The refractive income share has increased from approximately 25% in 2018 to 44% in 2022, while optometry income share rose from 7% to 16% [4] - The company is actively pursuing external growth opportunities, including acquisitions of established ophthalmology practices in strategic locations [5] - The competitive landscape in the ophthalmology sector is characterized by price transparency, with the company focusing on service quality and technological advancement to maintain a competitive edge [7] Future Outlook - The company projects a revenue target of 1.139 billion for the current year, with a net profit of over 38 million [7] - The anticipated growth in the ophthalmology sector is expected to continue, with the company aiming to align its growth with industry trends [7]

Business Focus and Strategy - The company reported a significant shift in its business focus towards ophthalmology services, transitioning from steel structure and clean energy sectors[17]. - The company is actively pursuing mergers and acquisitions to facilitate its strategic transformation in the healthcare sector[17]. - The company has established a dual-driven business model focusing on both steel structure and clean energy, with a recent pivot towards healthcare[16]. - The company plans to continue its market expansion and product development strategies to improve future performance[28]. - The company plans to accelerate the integration of auxiliary industries while concentrating resources on expanding its ophthalmology medical business over the next three years[91]. - The strategic focus includes regional development in key urban clusters such as the Yangtze River Delta and the Beijing-Tianjin-Hebei region, with a "1+6+N" model for expansion[91]. - The company aims to optimize its ophthalmology business structure by focusing on cataracts and fundus diseases, while also developing refractive surgery and other eye care services[91]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its service capabilities[120]. Financial Performance - The company's operating revenue for 2022 was ¥767,444,605.07, a decrease of 26.52% compared to ¥1,044,476,897.11 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥42,668,661.60, reflecting a significant decline of 311.82% from ¥78,217,640.10 in 2021[20]. - The net cash flow from operating activities decreased by 14.48% to ¥124,329,575.96 in 2022, down from ¥145,374,912.47 in 2021[20]. - The basic earnings per share for 2022 was -0.15 yuan, a drop of 314.29% compared to 0.09 yuan in 2021[20]. - Total assets at the end of 2022 were ¥1,557,450,440.86, a decrease of 14.84% from ¥1,834,597,029.60 at the end of 2021[20]. - The company reported a total of ¥212,850,504.77 in non-recurring gains and losses for 2022, compared to ¥107,518,359.13 in 2021[26]. - The company experienced a negative net profit attributable to shareholders in the first and second quarters of 2022, with losses of ¥36,074,792.53 and ¥27,602,037.33 respectively[24]. - The company reported a significant increase in operational costs, impacting overall profitability for the year[119]. Market and Industry Insights - The total number of eye disease patients in China exceeds 1 billion, with myopia and dry eye patients accounting for over 900 million, representing more than 65% of the population[29]. - The ophthalmology service market in China reached 103.7 billion RMB in 2019, with a CAGR of 20% from 2015 to 2019, and is projected to grow to 252.2 billion RMB by 2025, with a CAGR of 17.5%[29]. - The refractive surgery market in China was valued at 18.1 billion RMB in 2019, with a CAGR of 32.3% from 2015 to 2019, and is expected to reach 72.5 billion RMB by 2025, with a CAGR of 28.4%[30]. - The medical optometry market in China reached 22.8 billion RMB in 2019, with a CAGR of 26.2% from 2015 to 2019, and is projected to grow to 50.03 billion RMB by 2025, with a CAGR of 14.6%[31]. - National policies emphasize the importance of eye health, providing strong support for the development of the ophthalmology industry[33]. Operational Developments - The company operates 14 specialized ophthalmology hospitals and 2 optometry clinics across 10 major cities in China, focusing on comprehensive eye care services[35]. - The company has established a national chain network of ophthalmology hospitals, all of which are designated medical insurance institutions, enhancing accessibility for patients[36]. - The company has established a "dual center" for eye diseases, enhancing its research capabilities and academic standing in the ophthalmology field[41]. - The company actively collaborates with renowned institutions and experts to promote medical education and research, addressing the shortage of ophthalmology talent in China[41]. - The company has introduced advanced medical equipment, including the Zeiss VisuMax and Alcon LenSx systems, to provide diverse refractive solutions[44]. - The company has established a comprehensive medical quality management system, focusing on patient safety and service quality[49]. - The company has launched a new telemedicine platform, which is expected to increase patient engagement by 30%[129]. Governance and Compliance - The board has decided not to distribute cash dividends or issue bonus shares for the year[3]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, ensuring a complete and independent business operation[112]. - The board of directors consists of 9 members, including 3 independent directors, and has held 10 meetings throughout the year to ensure compliance with legal and regulatory requirements[109]. - The company has implemented a stock incentive plan and partner program to strengthen talent motivation and enhance corporate culture[103]. - The independent directors have confirmed compliance with all regulatory requirements, ensuring governance standards are met[127]. - The company has not faced any penalties from regulatory bodies, maintaining a clean compliance record[124]. Talent and Human Resources - The company has implemented a competitive compensation system and a restricted stock incentive plan to stabilize its talent pool[45]. - The company has strengthened its talent acquisition strategy, attracting renowned ophthalmology experts to enhance its medical team[43]. - The company has established a talent reserve mechanism combining "internal training + external introduction" to enhance its talent cultivation system and provide competitive compensation and development platforms for core management personnel[103]. - The company plans to continue its training programs, focusing on enhancing employees' professional and practical skills[166]. - The total number of employees at the end of the reporting period was 1,559, with 1,995 employees receiving salaries[163]. Research and Development - The company has identified accounting errors related to goodwill impairment testing, leading to restatements of previous financial reports[20]. - The company's research and development expenses dropped significantly by 78.39% to ¥855,676.89 due to a decrease in overall revenue and reduced investment in R&D projects[68]. - The company is investing in new product development, including advanced eye care technologies, with an allocated budget of 50 million RMB for R&D[129]. - The company has initiated a collaborative research and education program, establishing clinical research centers to enhance its academic capabilities[50]. Social Responsibility - The company continues to innovate in its long-term incentive mechanisms to stabilize its talent pool and enhance entrepreneurial motivation[54]. - The company established a special fund for children's eye health, focusing on treatment assistance for economically disadvantaged children with eye diseases[55]. - The company is committed to social responsibility by engaging in public welfare activities aimed at improving national eye health[100]. - The company provided over 1,000 job opportunities across various regions, contributing to local economic development and poverty alleviation efforts[188]. - The company actively participated in pandemic prevention and control efforts, contributing to vaccination and testing initiatives[187].